🩺 Diabetes
Forxiga (Dapagliflozin) — Complete Guide for Heart, Kidney, and Diabetes (2026)
How Forxiga (dapagliflozin) works for Type 2 diabetes, heart failure, and kidney disease. Side effects, dosing, and who should take it. Updated January 2026.
📅 Updated January 2026⏱ 9 min read👤 Dr. Priya Sharma, MD✓ Medically Reviewed
Key Takeaways
- Forxiga reduces heart failure hospitalisation by 26% in both diabetic and non-diabetic patients
- DAPA-CKD trial: Dapagliflozin slows kidney disease progression by 44%
- Forxiga is now approved for CKD without diabetes — a landmark first for SGLT2 inhibitors
- HbA1c reduction of 0.7–0.9% with modest weight loss of 2–3 kg
- Stop before surgery — sick day rules prevent rare but serious DKA risk
What Is Forxiga (Dapagliflozin)?
Forxiga is the brand name for dapagliflozin — an SGLT2 inhibitor approved for three separate conditions: Type 2 diabetes, heart failure (with or without diabetes), and chronic kidney disease (with or without diabetes). It works by blocking glucose reabsorption in the kidney, causing glucose to be excreted in urine.
26%
Reduction in heart failure hospitalisation (DAPA-HF)
44%
Slower CKD progression (DAPA-CKD trial)
10mg
Single dose used for all three indications
Three Landmark Trials
DECLARE-TIMI 58 — Cardiovascular Outcomes in T2D
In 17,160 patients with T2D and either established CVD or multiple CVD risk factors, dapagliflozin reduced hospitalisation for heart failure by 27% and slowed CKD progression. No significant reduction in major cardiovascular events in the overall population (unlike empagliflozin's EMPA-REG).
DAPA-HF — Heart Failure (Including Non-Diabetics)
In 4,744 patients with heart failure with reduced ejection fraction (HFrEF), dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% — regardless of diabetes status. This established Forxiga as a core heart failure medication for everyone, not just diabetics.
DAPA-CKD — Kidney Disease (Including Non-Diabetics)
In 4,304 patients with CKD (eGFR 25–75, uACR ≥200), dapagliflozin reduced the primary composite (sustained ≥50% eGFR decline, ESKD, CV death, or death) by 39% regardless of diabetes status. This led to the landmark approval for CKD without diabetes in 2021.
Dosing and How to Take It
- Dose: 10mg once daily for all indications (diabetes, heart failure, CKD)
- Timing: Morning preferred — mild diuretic effect better tolerated during waking hours
- With or without food: No significant effect on absorption
- Renal restriction: Not recommended for glucose lowering if eGFR below 45. Continue for CKD/HF benefit down to eGFR 25 (per trial data).
ℹ️ Forxiga vs Jardiance — How to Choose?
Both are excellent SGLT2 inhibitors with similar efficacy. Jardiance (empagliflozin) may have a slight edge for cardiovascular death reduction (EMPA-REG showed stronger CV mortality signal). Forxiga has the most robust CKD data (DAPA-CKD) and is approved for CKD across a wider eGFR range. In practice, both are used interchangeably based on formulary availability and individual patient factors.
Frequently Asked Questions
Can I take Forxiga if I have kidney disease?▼
Yes — Forxiga is specifically approved for CKD and is one of its primary indications. Continue down to eGFR 25 ml/min/1.73m² for kidney and heart failure protection. Do not use for glucose lowering below eGFR 45. The initial eGFR dip when starting (3–5 points) is haemodynamic, not damage — do not stop the drug for this alone.
What is the difference between Forxiga and Jardiance?▼
Both are SGLT2 inhibitors with similar efficacy. Key differences: Forxiga has stronger CKD outcome data (DAPA-CKD) and is approved for CKD + HF with or without diabetes. Jardiance may have a stronger cardiovascular death reduction signal (EMPA-REG: 38% CV death reduction vs Forxiga's less dramatic CV mortality effect). Both are NICE and ADA guideline recommended — choice depends on individual patient profile and availability.
Does Forxiga cause weight loss?▼
Yes — average weight loss is 2–3 kg, primarily from glucose excretion (70–80g glucose lost in urine daily = ~300 calories equivalent) and a mild diuretic effect. The weight loss is real but modest compared to GLP-1 drugs. Combining Forxiga with a GLP-1 drug produces additive weight loss effects.
Related Health Guides
⚕️ Medical Disclaimer: For informational purposes only. Always consult a qualified healthcare professional before starting or changing any medication.
Dr
Dr. Priya Sharma, MD
WellCalc Medical Contributor
All articles reviewed by qualified healthcare professionals following NHS, AHA, and WHO guidelines.